Clinical Trials Insight: 700053467
Latest Information Update: 23 Aug 2010
At a glance
- Drugs Bremelanotide (Primary) ; Type 5 cyclic nucleotide phosphodiesterase inhibitors
- Indications Erectile dysfunction
- Focus Therapeutic Use
Most Recent Events
- 17 Aug 2010 In the fourth quarter of 2010, Palatin Technologies expects to meet with the FDA to discuss initiation of this trial.